20-Aug-2018 09:00 AM
Citigroup today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2100p (from 1675p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
16-Aug-2018 08:30 AM
Peel Hunt today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to add (from hold) and raised its price target to 1950p (from 1160p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk.
15-Aug-2018 08:54 AM
Hikma Pharmaceuticals raised guidance Wednesday for its injectables and generics businesses after reporting a jump in first-half profits.
Injectables revenue is expected within a range of $775m to $825m and core operating margin for the full year to be
09-Aug-2018 09:20 AM
Numis today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to hold (from add).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
03-Jul-2018 08:20 AM
Citigroup today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1675p (from 1475p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
04-Jun-2018 09:55 AM
Hikma Pharmaceuticals said Monday it had appointed Henriette Nielsen as Chief Transformation Officer.
In this newly created role, Nielsen would be responsible for leading a number of initiatives across Hikma's global operations to improve operatio
18-May-2018 10:40 AM
Numis today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to add (from buy) and raised its price target to 1560p (from 1300p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
18-May-2018 08:43 AM
Hikma Pharmaceuticals reiterated its full-year guidance on Friday after reporting that its injectables, generics and branded businesses benefited from new product launches in the first four months of the year.
The company also said its efforts to reduce
01-May-2018 10:00 AM
Citigroup today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1475p (from 1250p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
20-Apr-2018 09:28 AM
Hikma Pharmaceuticals said Friday its wholly-owned US subsidiary West-Ward Pharmaceuticals launched an injection to reduce the incidence and severity of cardiomyopathy, a chronic heart disease, in certain women with breast cancer.
West-Ward launched Dex
20-Mar-2018 09:50 AM
Peel Hunt today reaffirms its hold investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 1160p (from 1180p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
15-Mar-2018 03:00 PM
Morgan Stanley today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1050p (from 1000p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk.
15-Mar-2018 01:50 PM
Citigroup today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from neutral) and set its price target at 1250p.
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
15-Mar-2018 01:20 PM
Jefferies International today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to hold (from underperform) and raised its price target to 997p (from 895p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.
15-Mar-2018 12:40 PM
JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1050p (from 1000p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk..
14-Mar-2018 08:26 AM
Hikma reported an operating loss of $747m in 2017 compared with a operating profit of $302m the previous year as increased competition in its US market weighed on its generics business.
Hikma's generics business reported an operating loss of $1,082
12-Mar-2018 01:49 PM
Hikma Pharmaceutical said a dispute resolution against the US Food and Drug Administration about the delayed launch of generic asthma treatment, VR315, had failed.
The company said it now anticipated new clinical data for the treatment to be submitted &a
01-Mar-2018 10:30 AM
Barclays Capital today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to underweight (from overweight) and cut its price target to 800p (from 1500p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.s
15-Feb-2018 08:10 AM
Peel Hunt today reaffirms its hold investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 1180p (from 1390p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
15-Jan-2018 09:39 AM
Hikma Pharmaceuticals has appointed Surendera Tyagi as group chief scientific officer and global head of research and development.
Dr Tyagi will focus on the group's non-injectables business during the first year and will become a member of Hikma
10-Jan-2018 12:20 PM
Jefferies International today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to underperform (from hold) and cut its price target to 895p (from 1074p).
Story provided by StockMarketWire.com...
04-Dec-2017 10:10 AM
Jefferies International today reaffirms its hold investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1074p (from 1045p).
Story provided by StockMarketWire.com...
01-Dec-2017 07:38 AM
Hikma Pharmaceuticals' venture capital arm, Hikma International Ventures and Development, has participated in a $20.5m series C round of financing for Prognos alongside Merck Global Health Innovation Fund, Safeguard Scientifics, Guardian Health, Cign
27-Nov-2017 01:49 PM
Hikma Pharmaceuticals has confirmed that its venture capital arm, Hikma Ventures invested in , the next generation minimally-invasive biosensor technology company, in collaboration with M Ventures which led the $10m series A round of financing.
Lana Ghan
14-Nov-2017 11:20 AM
Peel Hunt today reaffirms its hold investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and set its price target at 1390p.
Story provided by StockMarketWire.com...